Grants per year
Personal profile
Research Interests
Stem Cell Transplantation for Pediatric diseases Minimal residual disease in leukemia Neuroblastoma and its treatment Stem Cell differentiation Tumor vaccines.
I have been involved in Clinical research for Neuroblastoma and stem cell transplantation. I have also for the past 26 year have a laboratory that was focused on several projects such as: 1. Minimal Residual Disease in leukemia and neuroblastoma using WT1 gene as a marker. 2. Hematopoietic stem cell differentiation primarily on neural differentiation. 3. The use of RT-PCR to assess chimerism post transplant. 4. Stem cell processing and storage. 5. neuroblastoma tumor stem cell identification and its role in disease development.
My clinical focus has been related to Hematopoietic Stem Cell transplantation both autologous and allogeneic. I have also developed and participate at the national level in the development of therapeutic protocols for neuroblastoma , leukemia and lymphoma at the former Pediatric Oncology group and the Children's Oncology Group. Most recently I have been the Institutional PI for the Pediatric Immune Deficiency consortium developing protocols for the transplant of patients affected with immune deficiency disorders.
Certifications and Licenses
Pediatrics | |
Pediatric Hematology-Oncology |
Training Experience
1972 | Internship, University of Tel Aviv |
1977 | Residency, University of Arkansas Hospital |
1980 | Fellowship, University of Texas/MD Anderson Cancer Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, Facultad de Medicina de la UNAM
… → 1971
Research interests keywords
- Blood Cancer (leukemia and lymphomas)
- Pediatrics
- Stem Cells
- Transplantation
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
GVHD002: Safety Follow-Up Through 180 Days of Treatment with Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients who have Failed to Respond to Steroid Treatment for acute GVHD.
Chaudhury, S., Duerst, R. E., Kletzel, M. & Tse, W. T.
10/19/15 → 8/31/50
Project: Research project
-
SCT 0914: 13-TLEC Natural HIstory & Biology of Long-Term Late Effects Following HCT for Childhood Malignancies
National Marrow Donor Program, National Institutes of Health
12/16/14 → 12/15/17
Project: Research project
-
4 protocols:#6901-A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders#6902-Primary Immune Deficiency Treatment Consortium: Protocol #6902: A Retrospective
University of California at San Francisco, National Institute of Allergy and Infectious Diseases
9/1/14 → 8/31/20
Project: Research project
-
4 protocols:#6901-A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders#6902-Primary Immune Deficiency Treatment Consortium: Protocol #6902: A Retrospective
University of California at San Francisco, National Institute of Allergy and Infectious Diseases
9/1/14 → 8/31/19
Project: Research project
-
Primary Immune Deficiency Treatment Consortium
University of California at San Francisco, National Institute of Allergy and Infectious Diseases
9/1/13 → 8/31/14
Project: Research project
-
Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation
Bognàr, T., Bartelink, I. H., Egberts, T. C. G., Rademaker, C. M. A., Versluys, A. B., Slatter, M. A., Kletzel, M., Nath, C. E., Cuvelier, G. D. E., Savic, R. M., Dvorak, C., Long-Boyle, J. R., Cowan, M. J., Bittencourt, H., Bredius, R. G. M., Güngör, T., Shaw, P. J., Ansari, M., Hassan, M., Krajinovic, M., & 9 others , Apr 2022, In: Transplantation and Cellular Therapy. 28, 4, p. 196-202 7 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies
Rossoff, J., Jacobsohn, D., Kwon, S., Kletzel, M., Duerst, R. E., Tse, W. T., Schneiderman, J. & Chaudhury, S., Aug 2021, In: Pediatric Blood and Cancer. 68, 8, e29087.Research output: Contribution to journal › Article › peer-review
3 Scopus citations -
Veno-occlusive disease after high-dose busulfan–melphalan in neuroblastoma
Schechter, T., Perez-Albuerne, E., Lin, T. F., Irwin, M. S., Essa, M., Desai, A. V., Frangoul, H., Yanik, G., Dupuis, L. L., Jacobsohn, D., Kletzel, M., Ranalli, M., Soni, S., Seif, A. E., Grupp, S. & Dvorak, C. C., Mar 1 2020, In: Bone Marrow Transplantation. 55, 3, p. 531-537 7 p.Research output: Contribution to journal › Article › peer-review
14 Scopus citations -
Fecal calprotectin and serum albumin as markers of gastrointestinal graft versus host disease
Broglie, L., Rademaker, A., Galvin, J., Ray, A., Tse, W. T., Duerst, R., Schneiderman, J., Kletzel, M. & Chaudhury, S., Sep 2018, In: Hematology/ Oncology and Stem Cell Therapy. 11, 3, p. 169-174 6 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Gene therapy in patients with transfusion-dependent β-thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J. A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., Moshous, D., Lefrere, F., Puy, H., Bourget, P., Magnani, A., Caccavelli, L., Diana, J. S., Suarez, F., Monpoux, F., Brousse, V., & 27 others , Apr 19 2018, In: New England Journal of Medicine. 378, 16, p. 1479-1493 15 p.Research output: Contribution to journal › Article › peer-review
Open Access463 Scopus citations